# Diagnostic kit technologies available for licensing in India

URL: https://zernyxhub.com/blog/diagnostic-kit-technologies-to-license
Author: Dr. Abhay Tharmatt, Research Scientist, R&D, Zernyx Innovations
Published: 2026-11-05
Category: Licensing

> Diagnostic kit technology transfer in India: which kits ICMR has offered in 2026, kit formats compared, CDSCO IVD licences and a worked royalty example.

**Short answer:** Indian public institutes such as ICMR offer diagnostic kit technologies through Expression of Interest calls. ICMR's 2026 calls included a colorimetric LAMP assay for diphtheria at TRL 5, a dipstick kit for scrub typhus and an immunoassay for lymphatic filariasis. ICMR licences are non-exclusive by default at 2% of net sales. Manufacturing usually needs a CDSCO or state IVD licence.

A diagnostic kit looks simple from the outside: a box of reagents, a strip or a plate, and an instruction leaflet. From the bench it is anything but. Behind each kit are antibodies or primers that must behave the same way in every lot, buffers that must stay stable for months, and a validation data set that a regulator and a hospital buyer will both read.

That is why licensing a validated assay from a public institute can save a manufacturer years. The institute has done the discovery and the first validation. You bring manufacturing, quality systems and the route to market. This post covers which diagnostic kits Indian institutes have offered recently, how kit formats differ when you take them into production, what licences you still need, and the bench-level checks to run before you sign.

For medical devices in general (implants, apparatus, equipment), see our separate guide to [medical device technologies to license](https://zernyxhub.com/blog/medical-device-technologies-to-license). This post stays with diagnostic kits.

## Which diagnostic kits has ICMR offered in 2026?

ICMR publishes one Expression of Interest (EoI) per technology on its [call for proposals page](https://www.icmr.gov.in/call-for-proposals?archive=1&page=2), with applications through the Medical Innovation Patent Mitra portal. Three diagnostic calls from 2026 show the range. All three windows have closed, so treat them as examples of what comes up, and check the live page for current calls.

| Technology | Format | Developed at | Last date | What the call states |
|---|---|---|---|---|
| Colorimetric isothermal assay for *Corynebacterium diphtheriae* | LAMP, colour read-out | ICMR-NIV Mumbai Unit and ICMR-NIE Chennai | 20 May 2026 | TRL 5, third-party validated; Indian application 202111015391 and PCT/IN2022/050276; non-exclusive; 2% royalty on net sales |
| Dipstick test kit for *Orientia tsutsugamushi* (scrub typhus) | Dipstick | Not named in the listing | 8 July 2026 | Detection kit and method of detection |
| Immunoassay for infective and infected stages of lymphatic filariasis | Immunoassay | ICMR-NIVCR | 21 May 2026 | Screening assay |

The diphtheria call is the one I read in full ([EoI PDF](https://www.icmr.gov.in/icmrobject/uploads/Call/1778740574_icmr_eoi_rt_lamp_diptheria_nic_2026.pdf)). The assay targets two genes: *dtxR* to confirm the species and *tox* to flag toxigenic strains. External validation was done through the WHO office in Delhi at a diphtheria testing laboratory at KGMU, Lucknow. The EoI was published on 14 May 2026 with a six-day window, which tells you something practical: have your documents ready before the call appears.

ICMR has also issued calls of a different kind. A November 2026 EoI asks for information on ready-to-use multiplex assays for detecting enteric and respiratory pathogens in wastewater, with a last date of 25 November 2026. From its title it reads as a request for existing products, not a technology on offer, so read the document before treating it as a licensing opportunity.

## How do the kit formats compare in production?

The format decides what your plant needs, what your shelf-life problem will be and who buys the kit. This is the table I would want in front of me before choosing a technology.

| Format | Typical read-out | What production needs | Main bench headache | Usual buyer |
|---|---|---|---|---|
| Lateral flow or dipstick | Visual line on a strip | Membrane striping, conjugate spraying, cutting and housing | Line intensity varies lot to lot | Clinics, field programmes, pharmacies |
| ELISA | Colour in a 96-well plate, plate reader | Plate coating, blocking, drying, controlled assembly | Coating consistency and antibody supply | Hospital and reference labs |
| RT-PCR or PCR | Fluorescence on a thermocycler | Primer and probe synthesis, master mix, cold chain | Enzyme stability, contamination control | Molecular labs |
| LAMP and other isothermal | Colour change or fluorescence, heat block | Primer sets, isothermal enzyme mix, freeze-drying if possible | False positives from carry-over | District labs, field testing |

The diphtheria assay above is a colorimetric LAMP test. That format sits between PCR and a strip: it needs a stable temperature but no thermocycler, and a colour change can be read by eye. For a manufacturer already making PCR reagents, it is a natural fit. For one that only makes strips, it is a new production line.

**Strip kit or molecular kit? What changes on your shop floor**
Lateral flow or dipstick:
- No instrument at point of use
- Membrane and conjugate handling
- Lot-to-lot line intensity to control
PCR or LAMP:
- Heat block or thermocycler needed
- Enzymes and primers to source
- Cold chain or freeze-drying to plan
Pick the format your facility already knows how to make.

## Who can apply for an ICMR diagnostic EoI?

The diphtheria EoI lists pre-qualification criteria that are typical of ICMR calls. The applicant should:

1. Be a legal entity registered in India, with more than 51% of company stakes held by Indian promoters, with a GST registration or exemption certificate, or a PAN card.
2. Have manufacturing or R&D experience in the last three years, with a record of marketing similar products.
3. For commercial firms, have made no overall loss in the past three years.
4. Have a manufacturing unit in India and a functional R&D laboratory.
5. Hold GMP or ISO certification for manufacturing (or an approved Indian equivalent), and GLP or equivalent for R&D.
6. For commercial firms, not be blacklisted; and have no convictions of the firm or its promoters in the past three years.

The call also asks for a CDSCO licence for existing products, or evidence of similar products such as a brochure or a research paper. That call states no minimum turnover. The weekly production capacity figure was left blank in the template, so each call can set its own. Our step-by-step guide to [licensing from ICMR](https://zernyxhub.com/blog/license-technology-from-icmr) covers the documents and the e-EoI.

## Which licences do you still need to make the kit?

A technology licence gives you the right to use the IP and know-how. It does not allow you to make or sell an in vitro diagnostic (IVD). That comes under the Medical Devices Rules, 2017, administered by CDSCO and the state drug controllers.

[CDSCO's IVD page](https://cdsco.gov.in/opencms/opencms/hi/Medical-Device/InVitro-Diagnostics/) sets out the structure. IVDs are classified by risk into Class A (low), B (low to moderate), C (moderate to high) and D (high). The class depends on what the kit detects and its intended use, and CDSCO publishes a classification list for IVDs: the original list dated 23 July 2021, an update dated 25 October 2023, and a 6 February 2026 notice on risk classification in its online system. Find your analyte on that list first, because the class decides who licenses you.

| Step | Authority | Application form | Licence or permission |
|---|---|---|---|
| Test licence, to make kits for testing and evaluation | CDSCO | MD-12 | MD-13 |
| Clinical performance evaluation of a new IVD | CDSCO | MD-24 | MD-25 |
| Manufacturing licence, Class A or B | State Licensing Authority | MD-3 | MD-5 |
| Manufacturing licence, Class C or D | CDSCO (Central Licensing Authority) | MD-7 | MD-9 |

The forms are as listed on CDSCO's IVD page and its [Medical Devices Rules overview](https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/medical-device/RegulatoryMDR-2017.pdf). Fees follow the Second Schedule to the Rules. Budget the regulatory work as your own cost, and check the agreement for anything the institute has agreed to supply, such as validation data for the dossier.

**From signed licence to a kit you can sell**
1. Find the IVD class: From CDSCO's IVD classification list
2. Technology transfer: Protocols, reagents and training from the institute
3. Test licence: MD-12 application, MD-13 licence
4. Performance evaluation: MD-24 and MD-25 for a new IVD
5. Manufacturing licence: MD-5 from the state or MD-9 from CDSCO

## A worked royalty example

**Illustration with invented figures.** An MSME licenses a LAMP assay from an ICMR institute at the 2% royalty on net sales stated in the 2026 diphtheria EoI. After technology transfer and its manufacturing licence, it sells kits of 50 tests.

| Item | Amount |
|---|---|
| Kits sold in the first full year | 8,000 |
| Net price per kit, after GST and invoice discounts | ₹3,000 |
| Net sales | ₹2,40,00,000 |
| Royalty at 2% of net sales | ₹4,80,000 |
| Royalty per test (₹60 per kit ÷ 50 tests) | ₹1.20 |

Seen per test, the royalty is small next to enzymes, primers and packaging. The real costs of a kit licence are the technology transfer itself, validation lots and the regulatory work. Watch the definition of net sales in the agreement; [royalty base explained](https://zernyxhub.com/blog/royalty-base-net-sales) shows how a loose definition raises the bill.

## What should you check at the bench before signing?

This is where I would spend most of my time. A kit that worked in the inventor's lab can still fail in yours.

- Ask for the validation data: sample type, number of samples, reference method, sensitivity and specificity, and whether validation was independent. The diphtheria call states third-party validation; ask for the report itself.
- Trace the critical reagents. Where do the antibodies, antigens, enzymes or primers come from? If an antibody comes from a hybridoma held at the institute, you need the cell line or a supply agreement, often under a material transfer agreement.
- Read the stability data, real-time or accelerated, with the storage temperature and any freeze-drying step. A kit that needs freezer storage at minus 20 °C is a different business from one that ships at room temperature.
- Check lot-to-lot consistency by asking whether more than one lot has been made and compared. Most lab protocols have only ever been run as single batches.
- Confirm the IP coverage: application numbers, status and countries. The diphtheria assay has an Indian application and a PCT application; check the status of each on IP India's public search before you rely on it.

My honest opinion: run the protocol yourself in your own lab, on your own instruments, before you sign anything beyond an NDA. Two or three weeks of bench work tells you more than any data sheet. I cannot say how much an institute will help with this before signing, because it varies by institute and call, so ask the contact person named in the EoI.

## Common mistakes

- Applying for a format your plant has never made.
- Assuming the licence includes a supply of a critical reagent when the agreement is silent.
- Finding out the IVD class after signing, then discovering the kit needs a central licence.
- Treating TRL 5 as ready to manufacture. Scale-up, stability and lot consistency still lie ahead; [TRL for medical devices](https://zernyxhub.com/blog/trl-medical-devices) maps the remaining steps.

Calls appear without much warning and close fast. If you want to look across sources rather than one portal, [Zernyx Hub](https://www.zernyxhub.com) has mapped patents from universities across India, with AI business insight on each, including commercial applications.

## Common questions

### Who licenses diagnostic kit technologies in India?

ICMR publishes the most visible calls, issuing one Expression of Interest per technology on its Medical Innovation Patent Mitra portal. IITs, other central institutes and universities also license diagnostics through their technology transfer offices, usually on terms set in each agreement.

### What royalty does ICMR charge for a diagnostic kit?

ICMR's 2026 diphtheria assay EoI states a 2% royalty on net sales under its Guidelines for Technology Development Collaboration, with a non-exclusive licence. Read the EoI and agreement for your technology, because they set the binding terms.

### Do I need a CDSCO licence to make a licensed diagnostic kit?

In most cases. In vitro diagnostic devices are regulated under the Medical Devices Rules, 2017. CDSCO licenses manufacture of Class C and D IVDs (Form MD-7, licence MD-9), and the State Licensing Authority licenses Class A and B (Form MD-3, licence MD-5). CDSCO notes that non-sterile, non-measuring Class A devices are exempted from licensing, so check where your kit sits.

### Which diagnostic kit format is easiest to take to market?

It depends on your plant and buyers. Lateral flow and dipstick kits need no instrument at the point of use but are hard to make consistently. ELISA kits suit labs with plate readers. PCR and LAMP kits need enzymes, primers and a cold chain plan. Match the format to what your facility already makes.

---

Published by Zernyx Hub. More: https://zernyxhub.com/llms.txt
